Univest
Univest
  • Markets

Influx Healthtech Q4 FY26 Results: PAT Rs 2.1 Cr

  • May 21, 2026
  • Posted by: Neeraj Pandey
  • Category: News
No Comments
Influx Healthtech Q4 FY26 Results

Influx Healthtech Q4 FY26 results were declared on May 20, 2026. The company reported PAT of Rs 2.1 crore for the quarter ended March 31, 2026, up 16.7% YoY compared to Rs 1.8 crore in Q4 FY25. Revenue from operations stood at Rs 28.5 crore, up 17.8% YoY. Results are on a Consolidated basis. Influx Healthtech is a Healthcare Technology company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Influx Healthtech Q4 FY26 Financial Highlights
  • Influx Healthtech Q4 FY26 Performance Analysis
  • Key Factors Driving Influx Healthtech Q4 FY26 Results
    • Revenue Performance Q4 FY26
    • Profitability and Margin Analysis
    • FY27 Outlook
  • Frequently Asked Questions on Influx Healthtech Q4 FY26
    • What is Influx Healthtech Q4 FY26 net profit?
    • What is Influx Healthtech Q4 FY26 revenue?
    • When were Influx Healthtech Q4 FY26 results declared?
    • Is Influx Healthtech a good investment after Q4 FY26?

Influx Healthtech Q4 FY26 Financial Highlights

Metric Q4 FY26 (Rs Cr) Q4 FY25 (Rs Cr) YoY Change
Revenue 28.5 24.2 +17.8%
Net Profit 2.1 1.8 +16.7%
Basis Consolidated

Note: Q4 FY26 results declared May 20 2026. Healthcare technology solutions company. Verify from BSE/NSE audited filings before investment decisions.

Influx Healthtech Q4 FY26 Performance Analysis

The Influx Healthtech Q4 FY26 results reflect the company’s performance for the January to March 2026 quarter. The company delivered stable results in line with sector trends. Influx Healthtech operates in the Healthcare Technology sector, supported by India’s GDP growth above 6.5% and domestic demand momentum during FY26.

The 16.7% YoY PAT growth in Influx Healthtech Q4 FY26 reflects near-term profitability headwinds with management focus on cost management.

Screen the best stocks on the Univest Screener.

Key Factors Driving Influx Healthtech Q4 FY26 Results

Revenue Performance Q4 FY26

Influx Healthtech Q4 FY26 revenue of Rs 28.5 crore(up 17.8% YoY) reflects demand conditions in the Healthcare Technology sector during the January to March 2026 period. India’s macro environment with GDP above 6.5% and fiscal year-end demand supported business activity across sectors.

Profitability and Margin Analysis

The Influx Healthtech Q4 FY26 PAT of Rs 2.1 crore up 16.7% YoY. Sustaining and growing profitability will be the primary focus entering FY27.

FY27 Outlook

Following Influx Healthtech Q4 FY26 results, management guidance on FY27 revenue growth, margin improvement, and capital allocation will be key investor watchpoints. The Healthcare Technology sector continues to benefit from India’s long-term growth story, government policy support, and rising domestic consumption trends.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on Influx Healthtech Q4 FY26

What is Influx Healthtech Q4 FY26 net profit?

Ans. Influx Healthtech Q4 FY26 PAT of Rs 2.1 crore, up 16.7% YoY from Rs 1.8 crore in Q4 FY25. Results declared May 20, 2026 on a Consolidated basis.

What is Influx Healthtech Q4 FY26 revenue?

Ans. Influx Healthtech Q4 FY26 revenue was Rs 28.5 crore, up 17.8% YoY. Verify full audited breakdown from BSE/NSE filings.

When were Influx Healthtech Q4 FY26 results declared?

Ans. Influx Healthtech Q4 FY26 results were declared on May 20, 2026, at the board of directors meeting approving audited Q4 and FY26 financial statements.

Is Influx Healthtech a good investment after Q4 FY26?

Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is educational only. Consult a SEBI-registered financial advisor before investing in Influx Healthtech.



News Q4 Results
Author: Neeraj Pandey
Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.

Leave a Reply Cancel reply